(123) 456-7890 email@domain.com

Publications & News

Stay Up-To-Date with Prolong Pharmaceuticals
Publications
Conferences
News
References
  • STROKE

    • SANGUINATE® (PEGylated Carboxyhemoglobin Bovine) Improves Cerebral Blood Flow to Vulnerable Brain Regions at Risk of Delayed Cerebral Ischemia After Subarachnoid Hemorrhage. Neurocrit Care.

      2017 Dec; 27(3): 341-349 | Dhar R, Misra H, Diringer MN.

    • Investigational drugs for vasospasm after subarachnoid hemorrhage. Expert Opin Investig Drugs.

      2018 Apr; 27(4): 313-324 | Tallarico RT, Pizzi MA, Freeman WD.

    • Pharmacologically increasing collateral perfusion during acute stroke using a carboxyhemoglobin gas transfer agent (Sanguinate®) in spontaneously hypertensive rats. J Cereb Blood Flow Metab.

      2018 May; 38(5): 755-766 | Cipolla MJ, Linfante I, Abuchowski A, Jubin R, Chan SL.

  • SICKLE CELL DISEASE

    • Microvascular and systemic responses to novel PEGylated carboxyhaemoglobin-based oxygen carrier in a rat model of vaso-occlusive crisis. Artif Cells Nanomed Biotechnol.

      2019 Dec; 47(1): 95-103 | Nugent WH, Jubin R, Buontempo PJ, Kazo F, Song BK.

    • A Phase Ib open label, randomized, safety study of SANGUINATE® in patients with sickle cell anemia. Rev Bras Hematol Hemoter.

      2017 Jan-Mar;39(1):20-27 | Misra H, Bainbridge J, Berryman J, Abuchowski A, Galvez KM, Uribe LF, Hernandez AL, Sosa NR.

  • CYSTIC FIBROSIS

    • Targeting the Heme Oxygenase 1/Carbon Monoxide Pathway to Resolve Lung Hyper-Inflammation and Restore a Regulated Immune Response in Cystic Fibrosis. Front Pharmacol.

      2020 Jul 14; 11:1059 | Di Pietro C, Öz HH, Murray TS, Bruscia EM.

  • BLOOD NOT AN OPTION (BNAO – Case Reports)

    • Alternatives to Transfusion. Am J Clin Pathol.

      2020 Feb 8; 153(3): 287-293 | Bachert SE, Dogra P, Boral LI.

    • Bovine Hemoglobin-Based Oxygen Carrier Treatment in a Severely Anemic Jehovah's Witness Patient After Cystoprostatectomy and Nephrectomy: A Case Report. A Pract.

      2019 Apr 1;12(7):243-245 | Brotman I, Kocher M, McHugh S.

    • Investigational use of PEGylated carboxyhemoglobin bovine in a Jehovah's Witness with hemorrhagic shock. Transfusion.

      2018 Oct; 58(10): 2297-2300 | DeSimone RA, Berlin DA, Avecilla ST, Goss CA.

    • Pegylated Bovine Carboxyhemoglobin (SANGUINATE) in a Jehovah's Witness Undergoing Liver Transplant: A Case Report. Transplant Proc.

      2018 Dec; 50(10): 4012-4014 | Holzner ML, DeMaria S, Haydel B, Smith N, Flaherty D, Florman S.

    • Early Experiences With PEGylated Carboxyhemoglobin Bovine in Anemic Jehovah's Witnesses: A Case Series and Review of the Literature. J Pharm Pract.

      2020 Jun; 33(3): 372-377 | McConachie S, Wahby K, Almadrahi Z, Wilhelm S.

    • Pharmacotherapy in Acutely Anemic Jehovah's Witnesses: An Evidence-Based Review. Ann Pharmacother.

      2018 Sep; 52(9): 910-919 | McConachie SM, Almadrahi Z, Wahby KA, Wilhelm SM.

    • Pegylated bovine carboxyhaemoglobin utilisation in a thrombotic thrombocytopenic purpura patient. Transfus Med.

      2017 Aug; 27(4): 300-302 | Sam C, Desai P, Laber D, Patel A, Visweshwar N, Jaglal M.

    • Use of hyperbaric oxygen therapy and PEGylated carboxyhemoglobin bovine in a Jehovah's Witness with life-threatening anemia following postpartum hemorrhage. Int J Obstet Anesth.

      2017 Feb; 29: 73-80 | Thenuwara K, Thomas J, Ibsen M, Ituk U, Choi K, Nickel E, Goodheart MJ.

  • BLOOD NOT AN OPTION BNAO – Hemorrhagic shock

    • Resuscitation with PEGylated carboxyhemoglobin preserves renal cortical oxygenation and improves skeletal muscle microcirculatory flow during endotoxemia. Am J Physiol Renal Physiol.

      2020 May 1; 318(5): F1271-F1283 | Guerci P, Ergin B, Kandil A, Ince Y, Heeman P, Hilty MP, Bakker J, Ince C.

    • Improved Hemodynamic Recovery and 72-Hour Survival Following Low-Volume Resuscitation with a PEGylated Carboxyhemoglobin in a Rat Model of Severe Hemorrhagic Shock. Mil Med.

      2020 Aug 14;185(7-8):e1065-e1072 | Macko A, Sheppard FR, Nugent WH, Abuchowski A, Song BK.

    • Effects of Sanguinate on Systemic and Microcirculatory Variables in a Model of Prolonged Hemorrhagic Shock. Shock.

      2019 Oct;52(1S Suppl 1):108-115 | Nugent WH, Cestero RF, Ward K, Jubin R, Abuchowski A, Song BK.

  • OTHER NON-CLINICAL - Cardiovascular

    • PEGylated carboxyhemoglobin bovine (SANGUINATE) ameliorates myocardial infarction in a rat model. Artif Organs.

      2018 Dec;42(12):1174-1184 | Kawaguchi AT, Salybekov AA, Yamano M, Kitagishi H, Sekine K, Tamaki T.

    • The effect of SANGUINATE® (PEGylated carboxyhemoglobin bovine) on cardiopulmonary bypass functionality using a bovine whole blood model of normovolemic hemodilution. Perfusion.

      2020 Jan;35(1):19-25 | Romito BT, McBroom MM, Bryant D, Gamez J, Merchant A, Hill SE.

  • OTHER CLINICAL

    • A phase Ib, open-label, single arm study to assess the safety, pharmacokinetics, and impact on humoral sensitization of SANGUINATE infusion in patients with end-stage renal disease. Clin Transplant.

      2018 Jan;32(1) | Abu Jawdeh BG, Woodle ES, Leino AD, Brailey P, Tremblay S, Dorst T, Abdallah MH, Govil A, Byczkowski D, Misra H, Abuchowski A, Alloway RR.

  • REVIEW

    • SANGUINATE (PEGylated Carboxyhemoglobin Bovine): Mechanism of Action and Clinical Update. Artif Organs.

      2017 Apr; 41(4): 346-350. Abuchowski A.

Contact Us

 If you have any questions regarding our products or services, please contact us by phone or by completing the contact form and we will respond to  your inquiry at the earliest convenience.

Address
300 Corporate Court, Suite B
South Plainfield, NJ 07080 USA

Phone
(908) 444-4660 direct
(908) 444-4661 fax

Email
info@prolongpharma.com

Prolong Logo

1 + 5 =

Expanded Access Policy

Prolong Pharmaceuticals, LLC does not provide any drug in development to patients unless they have been accepted into one of our ongoing clinical trials.  For more information on our ongoing clinical trials, please contact info@prolongpharma.com